Semaglutide (Ozempic)
GLP-1 agonist · GLP-1 class · sc weekly · Novo Nordisk
Top dose
2.0 mg
HbA1c reduction
-2.20%
at week 40 · treatment policy
AE discontinuation
4.5%
Status
approved
Pivotal trial
- Trial
- SUSTAIN FORTE
- Indication
- type 2 diabetes
- Duration
- 40 weeks
- ClinicalTrials.gov
- NCT03989374
- Sponsor
- Novo Nordisk
Notes
SUSTAIN FORTE (Frias Lancet Diabetes Endocrinol 2021): semaglutide 2.0 mg HbA1c -2.2% vs 1.0 mg -1.9%, baseline 8.9%. The 2.0 mg high dose is approved.